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ABSTRACT: Light-triggered reversible modulation of physiological functions offers the promise of enabling on-demand spatiotemporally controlled thera-
peutic interventions. Optogenetics has been successfully implemented in the heart, but significant barriers to its use in the clinic remain, such as the need 
for genetic transfection. Herein, we present a method to modulate cardiac function with light through a photoswitchable compound and without genetic 
manipulation. The molecule, named PAI, was designed by introduction of a photoswitch into the molecular structure of an M2 mAChR agonist. In vitro 
assays revealed that PAI enables light-dependent activation of M2 mAChRs. To validate the method, we show that PAI photoisomers display different cardiac 
effects in a mammalian animal model, and demonstrate reversible, real-time photocontrol of cardiac function in translucent wildtype tadpoles. PAI can also 
effectively activate M2 receptors using two-photon excitation with near-infrared light, which overcomes the scattering and low penetration of short-wave-
length illumination, and offers new opportunities for intravital imaging and control of cardiac function. 
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Introduction 
Remote spatiotemporal control of physiological processes may 
provide novel treatment opportunities. Cardiopathies are paradig-
matic in this regard because of the rapid time course and complex 
integration of electrophysiological and molecular events in very 
specific areas of the heart. For instance, most cardiac rhythm con-
trol strategies rely on antiarrhythmic drugs (AADs) targeting ionic 
currents, whose effects cannot be regulated spatiotemporally. As 
a result, AADs often give rise to intolerable side effects, including 
ventricular pro-arrhythmogenicity, and are only partially effective. 
Overcoming the high failure and complication rates of current 
therapeutic strategies to treat these diseases will require both pa-
tient-personalized determination of the specific physiopathologi-
cal mechanism and qualitative pharmacological breakthroughs.1 
The application of light and optical techniques in medicine has had 
a profound impact over the last several decades, in diagnostics, 
surgery and therapy.2 In particular, photoexcitation of intrinsic 
molecules or exogenous light-sensitive agents introduced in the 
body can affect the tissues and cells within in various ways, via the 
generation of heat (photothermal), chemical reactions (photo-
chemical), and biological processes (photobiological/photophar-
macological or optogenetic).2 The potential of light as a 
therapeutic tool with high spatiotemporal resolution has been re-
cently investigated in the cardiovascular field, particularly for ar-
rhythmias, through optogenetics.3–7 However, the application of 
such genetic techniques to human subjects with therapeutic pur-
poses is still hampered by safety, regulatory and economic hur-
dles. Unlike optogenetics, photopharmacology rely on the use of 
exogenous light-regulated small molecules that can photocontrol 
native targets and that could be tested and approved using stand-
ard drug development procedures.8–15 These molecules can be 
used in combination with devices that deliver light to specific lo-
cations in the body7,16–18 in order to remotely control drug dosing 
and duration of action. Since the activity of drugs is structure-de-
pendent, reversible photoresponsive drugs are obtained by the ra-
tional introduction of a molecular photoswitch into the structure 
of a bioactive compound.8,14 
Cardiac function is controlled by the autonomic sympathetic and 
parasympathetic nervous systems, which act via adrenoceptors 
and muscarinic acetylcholine receptors (mAChRs), respectively.19 
In particular, stimulation of β1 and β2 adrenergic receptors in-
creases the heart rate (positive chronotropy) and contractility 
(positive inotropy), whilst stimulation of M2 mAChRs decreases 
heart rate and prolongs the atrioventricular conduction time.20,21 
Thus, adrenergic and muscarinic receptors constitute suitable tar-
get candidates to control cardiac function with light. Muscarinic 
acetylcholine receptors (mAChRs) belong to class A G protein-cou-
pled receptors (GPCRs) and are divided in five different subtypes 
(M1-M5).22 M2 receptor is extensively expressed in the heart. All 
five mAChRs are characterized by a high sequence homology in 
the orthosteric site located in the transmembrane region. This fact 
limits the development of subtype-selective orthosteric agonists. 
On the other hand, the allosteric site located in the extracellular 
loop is less conserved, thus muscarinic allosteric agents are com-
monly endowed with a more pronounced subtype-selectivity.23 A 
chemical strategy commonly applied to overcome such limitation 
is the incorporation, within the same molecular structure, of two 
distinct pharmacophore elements belonging to (a) high-affinity or-
thosteric agonists and (b) highly selective allosteric ligands.24–28 
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These hybrid compounds, termed “dualsteric” or “bitopic”, are ca-
pable to bind simultaneously to both the orthosteric and the allo-
steric sites of mAChRs and usually display valuable properties,29 
such as receptor subtype selectivity, functional selectivity,26,30 and 
higher tolerability in vivo.31 Moreover, such ligands bear in their 
structure two permanently charged nitrogen atoms, which likely 
prevent them from crossing the blood-brain barrier, confining 
their effects to the periphery, which is advantageous for cardio-
vascular agents. Herein, we describe the first non-genetic method 
for the optical control of cardiac function with a photoswitchable 
agonist. The design and synthesis of this molecule and its 
pharmacological characterization under one-photon (1P) and two-
photon (2P) excitation are reported.  
 
Results and Discussion 
Rational design, chemical synthesis and photochemical charac-
terization. Two novel putative photoresponsive muscarinic 
agents, named Phthalimide-Azo-Iperoxo (PAI) and Naphthalimide-
Azo-Iperoxo (NAI), were designed by replacing the polymethylene 
spacer chain of known M2 dualsteric agonists (P-8-Iper and N-8-
Iper)30–32 with a molecular photoswitch, while conserving (a) the 
 
Scheme 1. Chemical synthesis of PAI and NAI. 
Fig. 1. Chemical structures of the muscarinic ligands discussed in this work: the allosteric modulators W84 and Naphmethonium, the orthosteric agonist 
Iperoxo, the dualsteric agonists P-8-Iper and N-8-Iper, and the photoswitchable dualsteric ligands PAI and NAI. 
 
Iperoxo-like orthosteric agonist moiety, and (b) the M2-selective 
allosteric fragments derived from W84 and Naphmethonium (Fig. 
1). The incorporation of a photoisomerizable unit into the struc-
ture of a dualsteric agonist should enable controlling with light the 
mutual position of the orthosteric and the allosteric moieties, pre-
sumably leading to differences between the two isomers in recep-
tor affinity and efficacy. We chose an azobenzene core as photore-
sponsive component because of the favourable characteristics 
that azobenzene-based photoswitches normally display for bio-
logical purposes in comparison to other photoswitches, such as 
design flexibility, large changes in geometry upon isomerization, 
high photostationary states and fatigue resistance, fast pho-
toisomerization rates, and chemical stability, among others.33 
Moreover, the use of arylazo compounds has been proven safe in 
humans for some approved drugs and food colorants.33  
Fig. 3. PAI reversibly activates M2 mAChRs with light in calcium imaging assays. Real-time calcium imaging traces from HEK cells co-expressing 
M2mAChR and GqTOP loaded with 10 μM of the calcium indicator OGB1AM. a) Average trace of cell responses to 30 pM of non-photoswitchable musca-
rinic agonist IPX (n=130). Cells gave a sharp response to the application of IPX but, as expected, the concomitant application of pulses of UV or blue light 
did not alter calcium responses. b) Average trace of cell responses to 30 pM of trans-PAI (n=8). c) Single cell calcium responses induced by the direct 
application of 10 pM of trans-PAI (yellow bar). Purple bars indicate illumination at 365 nm, blue bars indicate illumination at 460 nm. Gray shadow in the 
recordings represents ±SEM. d) Quantification of photoresponses to the application of PAI (yellow bar) at 10 pM (n=356 cells from 5 different experiments) 
and 30 pM (n=293 cells from 6 different experiments), and recovery after 365 nm illumination (purple bar). Error bars are ± SEM. 
Fig. 2. Photochemical characterization. a) 2D and 3D representation of the chemical structures of trans- and cis-PAI. b) Absorption spectra of PAI 
showing distinct photochromic behaviour. c) The photoswitching process can be repeated over several cycles without noticeable photofatigue. 
 
PAI (1) and NAI (2) were prepared via two subsequent Menshutkin 
reactions between the azobenzene linker (4) and the correspond-
ing allo- and orthosteric intermediates (5 and 6, 9) (Scheme 1). 
Compound 3 was synthesized via the typical Mills reaction and 
successively brominated photochemically to afford the desired 
linker 4. Notably, this photochemical reaction exempted us from 
using a radical initiator34 and gave an excellent yield (96%), prov-
ing for the first time that light-induced benzylic halogenations can 
be conveniently used also for the preparation of such versatile 
photoswitchable linkers. Compounds 5, 6 and 9 were prepared as 
previously reported from commercially available starting materi-
als (Scheme 1 and SI).24–26,31 
As a prerequisite for a reversible light-dependent control of their 
biological activity, PAI and NAI need to effectively behave as re-
versible photoswitches, which means that the photoisomerization 
should be relatively fast and quantitatively significant in both di-
rections. UV/Vis spectroscopy experiments showed that PAI and 
NAI have the typical absorption bands of conventional azoben-
zenes. PAI can be isomerized to the cis form (about 73% conver-
sion) by applying 365 nm light, while it thermally relaxes back to 
the trans form in several hours at room temperature. It can be also 
effectively back-isomerized to the trans form by applying white or 
blue (460 nm) light (83% trans) (Fig. 2 and SI, Fig. S2). Surprisingly, 
NAI resulted refractory to photoisomerization (only 23% cis after 
10 min at 365 nm, SI, Fig. S2.1CD), which shows that rational de-
sign of azobenzene-containing ligands does not always afford the 
expected results. We hypothesized that the absorption and emis-
sion properties of the naphthalimide moiety35 could interfere with 
its photochromism. Given the unsatisfactorily photochromic be-
haviour of NAI, we selected only PAI for further studies.  
 
PAI allows reversible photo-activation of M2 mAChRs in calcium 
imaging experiments and molecular docking simulations. The 
photopharmacological properties of PAI were first assessed in 
vitro with real-time calcium imaging assays in transiently trans-
fected HEK cells under 1P-illumination (Fig. 3 and SI). We tested 
also the non-photoresponsive muscarinic agonist Iperoxo (IPX)36 
as a control (Fig. 3a). The application of trans-PAI (dark-adapted 
state) induced cytosolic calcium oscillations indicative of M2 ago-
nism, which were reduced by converting PAI to its cis form upon 
illumination with UV light (365 nm) (Fig. 3bc). Calcium oscillations 
could be restored after back-isomerizing PAI to the trans configu-
ration using blue light (460 nm). The time course of calcium re-
sponses during activation with trans-PAI displayed a diversity of 
behaviours in individual cells (Fig. 3c), including oscillatory waves, 
transient peaks, and step responses as previously observed with 
PLC-activating GPCRs.12 Quantification of photoresponses (ΔF/F0) 
to PAI application and 365 nm illumination shows a reduction in 
the calcium signal induced by UV light pulses (Fig. 3d). Intriguingly, 
PAI activated M2 mAChRs in the range of picomolar concentra-
tions, similarly to the super-agonist Iperoxo.36 Thus, we demon-
strated that PAI can effectively activate M2 mAChRs in vitro in its 
dark-adapted (trans) form and its activity can be reversibly 
switched off and on with light.In order to account for the observed 
photoswitchable activity of PAI in M2 mAChR, we looked for puta-
tive differences on the receptor level regarding binding efficacy of 
cis- and trans-PAI using molecular docking simulations (see SI for 
details). PAI isomers were docked into their theoretical binding 
site at the human M2 mAChR (PDB 4MQT). Our results suggested 
that trans-PAI can bind to the M2 mAChR in a typical dualsteric 
pose compatible with receptor activation (SI, Fig. S5.1a).37 In con-
trast, a flipped orientation is favoured in the case of the cis-isomer 
(SI, Fig. S5.1b). This binding pose is likely incompatible with recep-
tor activation and provides a possible explanation for the light-de-
pendent efficacy of PAI. 
 
Trans-PAI is more effective than cis-PAI at inducing bradycardia 
and PR lengthening in rats. Once established that PAI allows light-
dependent reversible activation of M2 mAChRs, we aimed at test-
ing it as an agent to photocontrol cardiac function in vivo. We ini-
tially used Wistar rats for our experiments. The intraperitoneal ad-
ministration of PAI induced progressive bradycardia and PR 
lengthening in a dose-dependent manner in both configurations 
(Fig. 4 and SI, Fig. S6.1). These effects were accompanied with 
 
Fig. 4. In vivo effect of trans- and cis-PAI on the cardiac activity of rats. The activity of dark-relaxed (trans, grey plots) and UV-illuminated PAI (cis, 
purple plots) administered intraperitoneally in anesthetized rats was tested by means of electrocardiography. The heart rate (left panel) and PR interval 
(right panel) are plotted as a function of increasing doses of both isomers, which induced progressive bradycardia and PR lengthening in a dose-dependent 
manner. Significant differences between the dark-relaxed and UV-treated PAI were found in the heart rate and PR interval at the higher doses (*p < 0.05; 
***p < 0.001 trans vs cis), in agreement with the higher agonist activity of the trans form observed in vitro and in tadpoles. Three rats in the trans-group 
died because of extreme bradycardia after the 100 µM/kg dose. The effects of PAI were reversible only upon administration of the muscarinic antagonist 
Atropine. 
 
variable degrees of systemic parasympathetic effects, such as sal-
ivation, urination and defecation. At low doses (≤ 3 µM/kg), both 
isomers yielded a similar small effect, but remarkably differed at 
intermediate and high doses. At 10 µM/kg PAI and higher doses, 
the PR interval was significantly more prolonged in trans; at 30 µM 
and higher doses, heart rate was also lower in trans. The effects of 
PAI could not be photoswitched either with blue or with UV light, 
showing that the ability of light to penetrate murine cardiac tissue 
at those wavelengths is likely not sufficient to reach M2 mAChR 
location. Only the administration of atropine (2 mg) completely 
reverted bradycardia, PR lengthening and systemic parasympa-
thetic effects in both groups (SI, Fig. S6.1). These results demon-
strated an enhanced parasympathetic activity for the trans-iso-
mer, and confirmed in mammals the previous findings observed in 
cells. 
 
PAI enables reversible photocontrol of cardiac activity in 
Xenopus tropicalis tadpoles. As an alternative to demonstrate 
reversible control of cardiac function in vivo, we turned to an ani-
mal model in which light scattering is known to be low thus allow-
ing better light penetration. We selected Xenopus tropicalis tad-
poles for this purpose since they are translucent and are recog-
nized as an excellent model for studying the human cardiovascular 
system (Fig. 5).38,39 Moreover, we had already successfully used 
video light microscopy to acquire real-time images of the develop-
ing beating heart by digitizing the expanding and contracting 
blood pool in early translucent hearts (Fig. 5a).38,40 
In the absence of PAI, the cardiac rate of tadpoles remained nearly 
constant at 2.3 ± 0.1 beats·s-1 during control illumination with UV 
light and at 2.10 ± 0.01 beats·s-1 in the dark. The variability score 
(V.S.) was 7.97 ± 0.07. Upon administration of 10 µM trans-PAI, 
heart rate decreased dramatically (0.41 ± 0.02 beats·s-1 in the 
trace of Fig. 5e) leading in some cases to cardiac arrest (Fig. 5c). 
Heart beating recovered progressively upon UV illumination (cis-
isomerisation, 1.28 ± 0.02 beats·s-1, Fig. 5f), and was not altered in 
the dark since thermal relaxation is slow. Some animals displayed 
less stable cardiac rate during UV periods compared to controls 
Fig. 5. Photoregulation of heart rate with PAI in frog tadpoles. a) Two video frames of a paralyzed tadpole heart indicating a region of interest (white 
circle) used to obtain the time course of heart beating movements (average of intensity versus time). b) Normal heartbeat recording obtained in control 
conditions (dim red light, indicated by a grey shade). Time scale: 2 s. c) Adding 10 μM trans-PAI under white light illumination reduces the heartbeat 
frequency, eventually causing cardiac arrest. d) Under UV illumination (purple shade), trans-PAI is isomerized to cis-PAI and heartbeat is recovered. e) Red 
traces indicate the heart rate (in beats·s-1, calculated every 15 s interval) as a function of time in 4 independent experiments with different animals. White, 
purple, and grey backgrounds indicate illumination with white, UV and dim red light, respectively. Heart rate is not altered by illumination under control 
conditions (SI Appendix, Fig. S6.2). Adding 10 μM trans-PAI under dim light reduces the heart rate in animals 2, 3 and 4. UV illumination isomerizes PAI 
to the cis form and the heart rate is partially recovered. Dim red light does not isomerize PAI (SI Appendix, Fig. S6.1) and heart rate is relatively stable. 
White light converts PAI to the trans isomer, causing cardiac arrest in all 4 animals. UV light restores heartbeat in all animals, some displaying an unstable 
rate. Several white/UV light cycles were repeated in some animals, showing similar effects. e) Quantification of heart rate during the last minute of each 
period (beats·s-1, n=4 tadpoles) in control conditions, under white light (trans-PAI) and under UV light (cis-PAI). f) Two-way for repeated measures 
ANOVA was performed with uncorrected Fisher’s LSD test, significance values were established with a p-value = 0.05. Error bars represent standard error 
of the mean (SEM). The heart rate was significantly higher under UV illumination compared to visible light (p-value < 0.05). Both isomers produced a 
significant reduction of heart rate in comparison to controls (p-value < 0.001). 
 
(V.S. of 17.4 ± 0.2 and 8.30 ± 0.02, respectively; SI, Fig. S7.3). Sub-
sequent illumination of the animals with visible light (cis-to-trans 
isomerization) again reduced cardiac rate and eventually inter-
rupted heart beating (V.S. of 374 ± 47.7, SI, Fig. S7.3). Cardiac ac-
tivity was restored by later exposition to UV light, and further 
UV/visible light cycles confirmed the reversibility of the pharma-
cological effects. (see example Supporting Movie S1). Overall, 
these experiments demonstrated that PAI allows remote and re-
versible control of heart rate with light in living animals. 
 
Activation of PAI with near infrared (NIR) light. In order to over-
come the scattering and low penetration of violet and visible illu-
mination, we tested whether PAI could be used to activate M2 
mAChRs at longer wavelengths. In fact, a critical aspect that must 
be addressed to unleash the full potential of light-regulated drugs 
and favour their translation into clinic is their responsiveness to 
red or NIR radiation,44,41 which enables higher penetration 
through tissue, abolishes photodamage and, in the case of 2P ex-
citation, allows three-dimensional subcellular resolution.42–46 PAI 
has an excellent thermal stability in both configurations (Fig. S2.3) 
and is photochemically suited for cis-to-trans photoisomerization 
with NIR light under 2P-excitation, which encouraged us to test its 
effects in living cells in real-time calcium imaging assays using a 
confocal microscope equipped with a pulsed laser. (Fig. 6). PAI was 
initially applied in its cis (off) state, which as expected did not pro-
duce cytosolic calcium oscillations. Subsequent illumination at 840 
nm induced robust calcium responses, as previously observed in 
calcium imaging experiments for cis-to-trans photoisomerization 
under 1P-excitation (Fig. 6a). These results are quantified in Fig. 
6c. The responses (ΔF/F0) obtained for cis-PAI (1P pre-irradiation 
at 365 nm) are comparable to controls, and 2P-induced isomeriza-
tion to trans-PAI achieves calcium responses nearly as high as per-
fusion of iperoxo. It is worth noting that even under NIR excitation 
PAI maintains an outstanding potency (picomolar) to activate M2 
mAChRs, which is rarely observed in photoswitches.11,44,47,48 Inter-
estingly, 2P microscopy is extensively used for intravital imaging 
including cardiovascular imaging at subcellular resolution.49,50 
Thus, PAI has a bright future to control cardiac function with light. 
 
Conclusion 
The rapid and reversible control of cardiac activity is of particular 
interest in medicine, including the spatiotemporal manipulation of 
Fig. 6. Activation of PAI with NIR light under 2P excitation. Real-time calcium imaging traces from HEK cells co-expressing M2 mAChR and GqTOP 
loaded with 10 μM of the calcium indicator OGB1AM. a) Average trace of cell responses to 30 pM cis-PAI pre-irradiated at 365 nm (purple bar), trans-
enriched PAI obtained under 2P excitation at 840 nm (red bar), and the muscarinic agonist IPX (green bar) after wash-out (wo, light blue bar) (n=29 cells). 
Neither 2P excitation alone (red panel) nor cis-PAI elicited calcium responses. Cells gave a sharp response upon application of pulsed NIR light (840 nm) in 
the presence of PAI as a consequence of its photoisomerization to the trans- active form. IPX was applied as a positive control. Gray shadow in the recordings 
represents ±SEM. b) Single cell calcium responses induced by PAI under 2P-excitation at 840 nm (red panel) (29 cells). Purple bar indicates application of 
pre-irradiated PAI (365 nm), red bar indicates illumination at 840 nm. c) Quantification of photoresponses of 29 cells to the application of cis-PAI (purple 
bar) at 30 pM, after switching to trans-PAI using 2P-excitation at 840 nm (red bar), control under 2P-excitation at 840 nm (grey bar) and IPX (green bar). 
Error bars are ± SEM. Data were analyzed by using one-way ANOVA with Sidak post hoc test for multiple comparisons for statistical significance (p-value 
(****) < 0.0001; GraphPad Prism 6).  
 
close anatomic structures bearing different electrophysiological 
functions in the heart. Light-activated cardiac drugs could be se-
lectively enhanced in certain regions of the heart (e.g., preventing 
undesired pro-arrhythmogenic ventricular effects when atria are 
targeted), or at certain times (on-demand, i.e., active only during 
atrial fibrillation or bradycardia). For that purpose, cardiac patches 
with integrated electronics and electric stimulation46 could be fur-
ther equipped with optoelectronic devices for photostimulation. 
Drug-based cardiac photoregulation techniques offer potential 
advantages compared to electric stimulation of cardiac muscle, 
which produces inhomogeneous areas of de- and hyperpolariza-
tion, causes faradaic reactions that alter pH, and produce toxic 
gases (H2, O2, Cl2), all of which would be prevented by light-stimu-
lation. 
To this end, we have developed the first photoswitchable com-
pound that enables control of cardiac activity with light in wildtype 
animals without genetic manipulation. To the best of our 
knowledge, PAI is also the first photoswitchable M2 mAChR ago-
nist to be reported. Despite the changes introduced in the ligand 
structure in order to photoregulate its activity, PAI retains the high 
potency of its parent compounds Iperoxo and P-8-Iper.31,36 PAI ac-
tivates M2 receptors in its trans configuration and can be reversi-
bly photoswitched with different wavelengths including NIR light 
under 2P excitation. Future experiments will be addressed to 
demonstrate that PAI enables precise spatiotemporal control of 





The Supporting Information is available free of charge on the ACS 
Publications website. Detailed materials and methods, synthetic 
procedures, chemical analyses, and any additional data and fig-
ures as noted in the text (PDF). 
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